used an IBM specific outcome measure for disease severity (IBM functional rating scale, IBMFRS [ 43 ]), identifying lower scores in patients harbouring NT5c1A antibodies, in contrast to seronegative patients; however, findings did not reach statistical significance (p = 0.06) [ 36 ].
← all excerpts
The health-related quality of life, mental health and mental illnesses of patients with inclusion body myositis (IBM): results of a mixed methods systematic review.
1
0.0600
0.0600